Valérie Lagarde

1.5k citations

27 papers · 1.2k indexed · h-index 14

Co-authors: François‐Xavier Mahon Françis Belloc Junia V. Melo John M. Goldman François Moreau‐Gaudry Claudine Chollet Josy Reiffers Jean‐Max Pasquet
Topics: Chronic Myeloid Leukemia Treatments (24 papers)Chronic Lymphocytic Leukemia Research (16 papers)Eosinophilic Disorders and Syndromes (10 papers)
Cited by: Hematology Genetics Rheumatology
Journals: SHILAP Revista de lepidopterologíaBlood PLoS ONE
Partner nations: France United Kingdom Switzerland

In The Last Decade

Valérie Lagarde

26 papers receiving 1.1k citations

Peers

Countries citing papers authored by Valérie Lagarde

Since Specialization

Citations

This map shows the geographic impact of Valérie Lagarde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valérie Lagarde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valérie Lagarde more than expected).

Fields of papers citing papers by Valérie Lagarde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valérie Lagarde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valérie Lagarde. The network helps show where Valérie Lagarde may publish in the future.

Co-authorship network of co-authors of Valérie Lagarde

This figure shows the co-authorship network connecting the top 25 collaborators of Valérie Lagarde. A scholar is included among the top collaborators of Valérie Lagarde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valérie Lagarde. Valérie Lagarde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient 2025 ·Annals of Hematology ·Grégoire Cullot,Valérie Lagarde,Jean-Michel Cayuela,Valérie Prouzet‐Mauleon,Béatrice Turcq,Yosr Hicheri,Lydia Roy,Thorsten Braun,Julien Mozziconacci,(unknown),Stéphanie Dulucq	0
2	Les effets du programme de soin sur le processus thérapeutique 2017 ·L information psychiatrique ·Valérie Lagarde,(unknown)	2
3	A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells 2017 ·Oncotarget ·(unknown),Valérie Prouzet‐Mauleon,Stéphane Claverol,Valérie Lagarde,Marc Bonneu,François‐Xavier Mahon,Bruno Cardinaud	19
4	Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation 2013 ·PLoS ONE ·Aurélie Bedel,Jean‐Max Pasquet,Éric Lippert,(unknown),Valérie Lagarde,Sandrine Dabernat,Pierre Dubus,(unknown),François Béliveau,Hubert de Verneuil,Emmanuel Richard,François‐Xavier Mahon,François Moreau‐Gaudry	24
5	Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence 2012 ·Cell Death and Disease ·Claire Drullion,(unknown),Valérie Lagarde,Sisareuth Tan,Romain Gioia,Muriel Priault,Mojgan Djavaheri‐Mergny,Alain Brisson,Patrick Auberger,(unknown),Jean‐Max Pasquet	74
6	Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells 2011 ·Blood ·Romain Gioia,Cédric Leroy,Claire Drullion,Valérie Lagarde,Gabriel Étienne,Stéphanie Dulucq,Éric Lippert,Serge Roche,François‐Xavier Mahon,Jean‐Max Pasquet	75
7	Induced Pluripotent Stem Cells (iPSC) From Chronic Myeloid Leukemia: Study of BCR-ABL Addiction and Effect of Tyrosine Kinase Inhibitors, 2011 ·Blood ·Aurélie Bedel,François Moreau‐Gaudry,Jean‐Max Pasquet,(unknown),Éric Lippert,Valérie Lagarde,Hubert de Verneuil,Emmanuel Richard,François‐Xavier Mahon	2
8	α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients 2011 ·Disease Markers ·(unknown),Maryse Dupouy,Patricia Costaglioli,Claudine Chollet,Valérie Lagarde,Jean‐Max Pasquet,Josy Reiffers,Bertrand Garbay,François‐Xavier Mahon,Béatrice Turcq	5
9	Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression 2008 ·Cancer Research ·François‐Xavier Mahon,Sandrine Hayette,Valérie Lagarde,Françis Belloc,Béatrice Turcq,Franck E. Nicolini,Coralie Bélanger,Paul W. Manley,Cédric Leroy,Gabriel Étienne,Serge Roche,Jean‐Max Pasquet	174
10	Proteomic analysis of an imatinib‐resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance 2008 ·PROTEOMICS ·(unknown),Valérie Lagarde,Gabriel Étienne,Maryse Dupouy,Delphine Lapaillerie,Stéphane Claverol,Sébastien Vilain,Marc Bonneu,Béatrice Turcq,François‐Xavier Mahon,Jean‐Max Pasquet	33
11	Lyn Kinase Overexpression Is One of the Mechanisms of Resistance to Nilotinib In Chronic Myeloid Leukemia 2008 ·Blood ·(unknown),Sandrine Hayette,Valérie Lagarde,Franck E. Nicolini,Françis Belloc,Cédric Leroy,Serge Roche,Paul W. Manley,Coralie Bélanger,Gabriel Étienne,Jean‐Max Pasquet	2
12	Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia 2006 ·Leukemia ·(unknown),Valérie Lagarde,Gabriel Étienne,Jean‐Antoine Ribeil,Stéphane Claverol,Marc Bonneu,François Moreau‐Gaudry,Veronique Guyonnet‐Dupérat,Olivier Hermine,J V Melo,(unknown),Béatrice Turcq,(unknown),Jean‐Max Pasquet	84
13	Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr‐Abl–positive cells 2004 ·Cytometry Part A ·Vanessa Desplat,Valérie Lagarde,Françis Belloc,Claudine Chollet,Thibaut Leguay,Jean‐Max Pasquet,Vincent Praloran,François‐Xavier Mahon	14
14	Overproduction of BCR‐ABL induces apoptosis in imatinib mesylate‐resistant cell lines 2004 ·Cancer ·Vanessa Desplat,Françis Belloc,Valérie Lagarde,(unknown),Junia V. Melo,Josy Reiffers,Vincent Praloran,François‐Xavier Mahon	10
15	The Proteome Analysis of an Imatinib-Resistant Cell Line Identifies Changes in Molecular Chaperones Such as Heat Shock Proteins (Hsp): A Possible New Mechanism of Imatinib Resistance. 2004 ·Blood ·Jean‐Max Pasquet,(unknown),Valérie Lagarde,Béatrice Turcq,Josy Reiffers,Junia V. Melo,François‐Xavier Mahon	2
16	Generation of Resistance Cell Lines to AMN107, a New Inhibitor of BCR-ABL and Its Effects on Cell Lines Sensitive and Resistant to Imatinib. 2004 ·Blood ·François‐Xavier Mahon,Valérie Lagarde,Paul W. Manley,Jean‐Max Pasquet,Béatrice Turcq,Josy Reiffers	4
17	MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models 2003 ·Blood ·François‐Xavier Mahon,Françis Belloc,Valérie Lagarde,Claudine Chollet,François Moreau‐Gaudry,Josy Reiffers,John M. Goldman,Junia V. Melo	426
18	Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs 2002 ·Leukemia ·(unknown),F-X Mahon,(unknown),Valérie Lagarde,JM Goldman,JV Melo	67
19	Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571 2002 ·Leukemia ·Reza Tabrizi,F-X Mahon,Pascale Cony Makhoul,Valérie Lagarde,Francis Lacombe,P. Berthaud,JV Melo,Josy Reiffers,Françis Belloc	7
20	Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571 2002 ·British Journal of Haematology ·Christophe Barthe,(unknown),Valérie Lagarde,Claudine Chollet,Pascale Cony‐Makhoul,Josy Reiffers,John M. Goldman,Junia V. Melo,François Xavier Mahon	37

About Valérie Lagarde

Valérie Lagarde is a scholar working on Hematology, Genetics and Rheumatology, having authored 27 papers that have together received 1.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (24 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Eosinophilic Disorders and Syndromes (10 papers). The work is most often cited by research in Hematology (710 citations), Genetics (508 citations) and Rheumatology (295 citations). Valérie Lagarde has collaborated with scholars based in France, United Kingdom and Switzerland. Frequent co-authors include François‐Xavier Mahon, Françis Belloc, Junia V. Melo, John M. Goldman, François Moreau‐Gaudry, Claudine Chollet, Josy Reiffers, Jean‐Max Pasquet, Gabriel Étienne and Béatrice Turcq. Their work appears in journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact